Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 induction study of ustekinumab in moderately to severely active Crohn's disease
2010-022759-42Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Ustekinumab with Placebo (2 arms). Primary endpoint: Clinical response at Week 6. Started May 2011; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2010-022759-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022759-42.